Results 1 to 10 of about 8,228 (234)

HALP score in Demodex blepharitis: A case–control study [PDF]

open access: yesOpen Medicine
Demodex mite infestation is one of the most prevalent causes of blepharitis. This study was designed to evaluate whether Demodex blepharitis was related to novel inflammatory markers.
Cakir Nuri   +4 more
doaj   +3 more sources

Demodex blepharitis: literature review [PDF]

open access: yesКлиническая офтальмология
S.V. Yanchenko1, A.V. Malyshev2,3, Sh.Zh. Teshaev1, G.R. Odilova1, G.B. Zhuraeva1 1Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara,   Republic of Uzbekistan 2Scientific Research Institute — Regional Clinical ...
S.V. Yanchenko   +4 more
doaj   +3 more sources

Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis. [PDF]

open access: yesClin Ophthalmol, 2023
PURPOSE: To obtain consensus on Demodex blepharitis (DB) treatment using a modified Delphi panel process. METHODS: Literature search identified gaps in knowledge surrounding treatment of DB.
Farid M   +11 more
europepmc   +4 more sources

Association Between Demodex Infestation and Ocular Surface Microbiota in Patients With Demodex Blepharitis [PDF]

open access: yesFrontiers in Medicine, 2020
Purpose: The aim of this study was to compare the ocular microbial communities in humans with and without demodex blepharitis in order to elucidate the relationship between ocular microorganisms and demodex infestation.Methods: Bacterial 16S rRNA genes ...
Yan Yan   +13 more
doaj   +5 more sources

Clinical diagnosis and management of Demodex blepharitis: the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH). [PDF]

open access: yesEye (Lond), 2023
BACKGROUND: Twelve ocular surface disease experts convened to achieve consensus about Demodex blepharitis (DB) using a modified Delphi panel process.
Ayres BD   +11 more
europepmc   +4 more sources

Demodex Blepharitis: A Survey-Based Approach to Investigate Knowledge, Attitudes, and Practices Among Optometrists in India [PDF]

open access: yesClinical Optometry, 2023
Nikhil Sharma,1 Eilidh Martin,1 Edward Ian Pearce,1 Suzanne Hagan,1 Christine Purslow2 1Department of Vision Sciences, Glasgow Caledonian University, Glasgow, Scotland, UK; 2School of Optometry and Vision Sciences, Cardiff University, Cardiff, Wales ...
Sharma N   +4 more
doaj   +3 more sources

Comparison of the Diagnosis and Management of Demodex Blepharitis Between Eye Care Practitioners in India and Australasia - A Survey-Based Comparison. [PDF]

open access: yesClin Optom (Auckl)
Aim: The primary aim of this study was to compare how eyecare professionals in disparate regions of the world diagnose and manage Demodex blepharitis.
Sharma N   +5 more
europepmc   +4 more sources

Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies. [PDF]

open access: yesEye Contact Lens, 2023
Demodex blepharitis is a common disease of the eyelid, affecting approximately 25 million Americans. This article reviews what is known about the mechanisms and impact of Demodex blepharitis, risk factors, signs and symptoms, diagnostic techniques ...
Rhee MK   +10 more
europepmc   +4 more sources

Psychosocial Impact of Demodex Blepharitis. [PDF]

open access: yesClin Ophthalmol, 2022
To evaluate the impact of Demodex blepharitis on patients' daily activities and quality of life.In this multicenter, observational, prospective, IRB-approved study, 311 Demodex blepharitis patients aged ≥18 years were included. Demodex blepharitis was diagnosed based on the presence of ≥1.0 mite per lash (upper and lower eyelids combined), >10 ...
O'Dell L   +7 more
europepmc   +4 more sources

Safety and Efficacy of Lotilaner Ophthalmic Solution (0.25%) in Treating Demodex Blepharitis: Pooled Analysis of Two Pivotal Trials. [PDF]

open access: yesOphthalmol Ther
Lotilaner ophthalmic solution (0.25%) is the first United States Food and Drug Administration (US FDA)-approved drug for treating Demodex blepharitis.
Yeu E   +15 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy